Journal
VACCINE
Volume 25, Issue -, Pages B89-B96Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.04.091
Keywords
immunotherapy; vaccine; clinical protocols; prostate cancer; prostate-specific antigen; cancer vaccine; combination therapy; hormone therapy; chemotherapy; radiation therapy; Anti-CTLA-4
Categories
Funding
- Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
Ask authors/readers for more resources
Novel strategies are emerging from preclinical and clinical investigations for combining vaccines with conventional and experimental anticancer therapies. Several lines of research show that combining either radiation or certain chemotherapeutic agents with vaccine can alter the phenotype of tumor cells, rendering them more susceptible to T cell-mediated killing. Furthermore, there is emerging data suggesting that an immune response elicited by vaccine may augment the antitumor effectiveness of subsequent therapies. This article reviews and discusses therapeutic cancer strategies that employ vaccines sequentially or in combination with conventional cytotoxic therapies such as local radiation, chemotherapy, and hormone therapy, or immunopotentiating therapies such as anti-CTLA-4 monoclonal antibodies. Preliminary results of clinical studies using these combination strategies have demonstrated a postvaccination antigen cascade, prolonged time to disease progression, and preliminary evidence of improved overall survival. Large randomized studies are currently underway to further investigate these findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available